Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: Results from a randomized open trial

Pediatric Infectious Disease Journal

Volumn 30, Issue 12, 2011, Pages

  Wheeler, Cosette M ^a   Harvey, Bryan M ^b   Pichichero, Michael E ^c   Simon, Michael W ^b   Combs, Stephen P ^d   Blatter, Mark M ^e   Marshall, Gary S ^f   Catteau, Grégory ^g   Dobbelaere, Kurt ^g   Descamps, Dominique ^g   Dubin, Gary ^h   Schuind, Anne ^h  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b Department of Harvey Pediatrics ^*  (United States)

^c Legacy Pediatrics   (United States)

^d Gray Station Pediatrics   (United States)

^e Pediatric Alliance   (United States)

^f University of Louisville School of Medicine   (United States)

^g GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^h GLAXOSMITHKLINE   (United States)

Author keywords

adolescent; diphtheria tetanus acellular pertussis vaccine; human papillomavirus vaccine; immunology; tetravalent meningococcal vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; MENINGOCOCCUS VACCINE; WART VIRUS VACCINE;

ADOLESCENT; ADOLESCENT DISEASE; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CHILD; CHILDHOOD DISEASE; DELTOID MUSCLE; DIPHTHERIA; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; MULTICENTER STUDY; MYALGIA; OPEN STUDY; PAPILLOMAVIRUS INFECTION; PATIENT COMPLIANCE; PERTUSSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TETANUS; TREATMENT OUTCOME; URTICARIA; UTERINE CERVIX CANCER; VACCINATION;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; ANTIGENS, BACTERIAL; ANTIGENS, VIRAL; CHILD; COHORT STUDIES; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HUMANS; MENINGOCOCCAL VACCINES; PAPILLOMAVIRUS VACCINES; VACCINES, CONJUGATE;

EID: 81855197029     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31822d28df     Document Type: Article

References (39)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189:12-19. (Pubitemid 29406813)
2. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-265. (Pubitemid 34293391)
3. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527. (Pubitemid 36159887)
4. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a metaanalysis update. Int J Cancer. 2007;121:621-632. (Pubitemid 46986496)
5. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128:927-935.
6. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191:182-192. (Pubitemid 40096375)
7. Moscicki AB. HPV infections in adolescents. Dis Markers. 2007;23:229-234.
8. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1-34.
9. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54:1-21.
10. Cervarix Prescribing Information, January 2011. Available at: http://us.gsk. com/products/assets/us-cervarix.pdf. Accessed May 12, 2011.
11. Boostrix Prescribing Information, January 2011. Available at: http://us.gsk. com/products/assets/us-boostrix.pdf. Accessed May 12, 2011.
12. Menactra Prescribing Information. Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, August 2010. Available at: http://www.menactra.com/prescribing-information. html. Accessed May 12, 2011.
13. Camargo ME, Silveira L, Furuta JA, et al. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J Clin Microbiol. 1984; 20:772-774. (Pubitemid 14006079)
14. Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzymelinked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand. 1983;11:137-144. (Pubitemid 13053038)
15. Granstrom M, Lindberg AA, Askelof P, et al. Detection of antibodies in human serum against the fimbrial haemagglutinin of Bordetella pertussis by enzyme-linked immunosorbent assay. J Med Microbiol. 1982;15:85-96. (Pubitemid 12180871)
16. Granstrom M, Granstrom G, Lindfors A, et al. Serologic diagnosis of whooping cough by an enzyme-linked immunosorbent assay using fimbrial hemagglutinin as antigen. J Infect Dis. 1982;146:741-745. (Pubitemid 13211870)
17. Dessy FJ, Giannini SL, Bougelet CA, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin. 2008;4:425-434.
18. Wassilak SGF, Roper MH, Murphy TV, et al. Tetanus toxoid. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 4th ed. Philadelphia, PA: Saunders; 2004:745-781.
19. Wharton M, Vitek CR. Diphtheria toxoid. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 4th ed. Philadelphia, PA: Saunders; 2004:211-228.
20. Maslanka SE, Gheesling LL, Libutti DE, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol. 1997;4:156-167. (Pubitemid 27130227)
21. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780-786. (Pubitemid 37129487)
22. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine. 2005;23:2222-2227. (Pubitemid 40341456)
23. Weston WM, Friedland LR, Wu X, et al. Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration. Vaccine. 2011;29:1017-1022.
24. Garcia-Sicilia J, Schwarz TF, Carmona A, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health. 2010;46:142-151.
25. Macalalad N, Aplasca-De Los Reyes MR, Dimaano E, et al. The candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (MenACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. Presented at: Third Northern European Conference on Travel Medicine; May 26-29, 2010; Hamburg. Abstract: A-260-0002-00112.
26. Østergaard L, Silfverdal SA, Schade Larsen C, et al. The candidate meningococcal serogroups A, C, W-135, Y conjugate vaccine (Men-ACWY-TT) coadministered with a combined hepatitis a and b vaccine (HepA/B) is immunogenic and well-tolerated in subjects aged 11-17 years. Presented at: Third Northern European Conference on Travel Medicine; May 26-29, 2010; Hamburg. Abstract: A-260-0002-00110.
27. Pichichero ME, Blatter MM, Kennedy WA, et al. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics. 2006;117:1084-1093. (Pubitemid 46071499)
28. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301-314.
29. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564-571. (Pubitemid 46771257)
30. Didierlaurent AM, Morel S, Lockman L, et al. AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol. 2009;183:6186-6197.
31. Vesikari T, Van DP, Lindblad N, et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J. 2010;29: 314-318.
32. Reisinger KS, Block SL, Collins-Ogle M, et al. Safety, tolerability, and immunogenicity of Gardasil given concomitantly with Menactra and Adacel. Pediatrics. 2010;125:1142-1151.
33. Arguedas A, Soley C, Loaiza C, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine. 2010;28:3171-3179.
34. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009;5:332-340.
35. Verstraeten T, Descamps D, David MP, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 2008;26:6630-6638.
36. Wacholder S, Chen BE, Wilcox A, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ. 2010;340:c712.
37. Frampton JE, Keating GM. Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Boostrix): a review of its use as a singledose booster immunization. BioDrugs. 2006;20:371-389. (Pubitemid 46091590)
38. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159:907-913. (Pubitemid 41423328)
39. Kroger AT, Atkinson WL, Marcuse EK, et al. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1-4.